Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
Ad hoc Mitteilung gemäss Art. 53 KRBaar, Schweiz, 22. April 2026Die Aktionärinnen und Aktionäre der Ascom Holding AG haben an der ordentlichen Generalversammlung vom 22. April 2026 in Zug allen...
-
Ad hoc announcement pursuant to Art. 53 LRBaar, Switzerland, April 22, 2026At the Annual General Meeting held on April 22, 2026, in Zug, the shareholders of Ascom Holding AG approved all proposals...
-
SEALCOIN Advances Infrastructure for the Machine Economy, Leveraging Hedera Network and Post-Quantum Cryptography Expertise Zug, Switzerland - April 22, 2026 — WISeKey International Holding Ltd...
-
Late-breaking Phase III FENhance 1 and 2 study results showed superiority of investigational fenebrutinib compared to teriflunomide in reducing relapses and brain lesions in relapsing multiple...
-
Washington, D.C., USA, April 21, 2026 (GLOBE NEWSWIRE) -- ABB’s microgrid-ready UPS architecture integrates battery storage, renewables, and gas generation for resilience and flexibility for AI data...
-
NEW YORK, April 21, 2026 (GLOBE NEWSWIRE) -- 21shares, one of the world’s largest issuers of cryptocurrency exchange traded products (ETPs), today announced its expected distribution dates of...
-
Phase III METEOROID study met its primary endpoint in patients with myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD)MOGAD is a rare autoimmune disease of the central nervous...
-
21Shares AG LEI: 254900UWHMJRRODS3Z64 21 April 2026 Publication of Base Prospectus The following Base Prospectus has been approved by the Financial Conduct Authority and is available for...
-
Investors can now capture rewards from the protocol commanding over 50% of DEX perpetual open interest Zurich, 21 April 2026 – 21shares, a global leader in cryptocurrency exchange-traded products...
-
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, April 21, 2026 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a...